Form 10-Q · Quarterly report
Stryker Corporation 10-Q, filed Jul 31, 2026
- Filed
- CIK
- 0000310764
- Accession no.
- 0000310764-26-000050
Summary
Stryker Corporation reported 2026 second-quarter net sales of $6,589 million, up 9.4% from a year earlier, and adjusted net earnings per diluted share of $3.69, up 17.9%. First-half net sales rose 6.1% to $12,609 million, with adjusted net earnings per diluted share of $6.29.
Key points
- Second-quarter net sales rose 9.4% as reported and 9.0% in constant currency; first-half net sales rose 6.1% as reported and 5.0% in constant currency.
- Second-quarter net earnings were $1,276 million, or $3.30 per diluted share; adjusted net earnings per diluted share were $3.69, up 17.9% year over year.
- First-half net earnings were $2,021 million, or $5.23 per diluted share; adjusted net earnings per diluted share were $6.29, up 5.4% year over year.
- Second-quarter gross profit margin rose to 68.3% from 63.8%, helped by a reduction of certain import tariffs and lower amortization of inventory stepped up to fair value.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ABOUT STRYKER Stryker Corporation ("we" or the "Company") is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology, and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.